Myeloproliferative Neoplasms | Specialty

The OncLive Myeloproliferative Neoplasms condition center is a comprehensive resource for clinical news and expert insights on myeloproliferative neoplasms, including myelofibrosis, polycythemia vera, and essential thrombocythemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in myeloproliferative neoplasms.

Selecting a Therapy for Patients With MF

February 21st 2022

A panel of experts share how they select between treatment options for patients with MF.

More Upfront Therapy Options for MF

February 21st 2022

More upfront therapy options for the MF treatment landscape are discussed, including the safety profiles of these drugs.

Pelabresib Monotherapy Shows Benefit in JAK Inhibitor–Naïve Advanced Myelofibrosis

February 17th 2022

Marina Kremyanskaya, MD, PhD, discusses the safety and efficacy of pelabresib in patients with myelofibrosis, additional data from the MANIFEST trial, and other efforts investigating the agent in this disease.

Determining Treatment for MF And Upfront Therapy Options

February 14th 2022

A group of experts explain how to determine treatment for each patient with MF, as well as upfront therapy options.

More About MF Prognosis, Biomarkers, and Treatment

February 14th 2022

The panel continues the MF prognosis discussion while also discussing biomarkers and treatment for the disease.

MF Prognosis and Common Risks

February 7th 2022

Drs Shammo and Mesa explain the MF prognosis and possible risk factors.

A Myelofibrosis Diagnosis

February 7th 2022

Dr Fleischman provides details about myelofibrosis (MF) and what factors are considered with a diagnosis.

Orca-T Graft Improves Outcomes in Myelofibrosis Following Allogeneic Stem Cell Transplant

February 4th 2022

Arpita Gandhi, MD, discusses a subgroup analysis of patients with myelofibrosis who received Orca-T and how this type of therapy could be a game-changer for this patient population.

EU Panel Recommends Avapritinib for Advanced Systemic Mastocytosis

January 31st 2022

The European Medicines Agency’s Committee for Medicinal Products for Human Use recommended to expand the current indication for avapritinib to include single-agent use in patients with aggressive systemic mastocytosis, systemic mastocytosis with an associated hematological neoplasm, or mast cell leukemia.

Dr. Verstovsek on the Tolerability of Momelotinib in Myelofibrosis

January 28th 2022

Srdan Verstovsek, MD, PhD, discusses the tolerability of momelotinib in myelofibrosis.

Dr. Gerds on Emerging Agents in Myelofibrosis

January 27th 2022

Aaron T. Gerds, MD, MS, discusses emerging agents in myelofibrosis.

FDA Places Partial Clinical Hold on Trials Examining Magrolimab Plus Azacitidine in MDS, AML, and Myeloid Malignancies

January 27th 2022

The FDA has placed a partial clinical hold on clinical trials evaluating the combination of magrolimab and azacitidine after an apparent imbalance in investigator-reported, suspected unexpected serious adverse reactions observed between study arms.

Dr. Mesa on the Unique Characteristics of Momelotinib in Myelofibrosis

January 26th 2022

Ruben A. Mesa, MD, discusses the unique characteristics of momelotinib in myelofibrosis.

Momelotinib Significantly Improves Symptoms, Anemia, and Splenic Size in Myelofibrosis

January 25th 2022

Momelotinib provided a statistically significant benefit in terms of splenic symptoms, anemia, and splenic size in patients with myelofibrosis.

FDA Grants Orphan Drug Designation to Eltanexor for Myelodysplastic Syndromes

January 24th 2022

The FDA has granted an orphan drug designation to eltanexor, an investigational novel SINE compound, as a potential therapeutic option for patients with myelodysplastic syndromes.

What to Know About Polycythemia Vera and Treatment Options

January 24th 2022

Angela Fleischman, MD, PhD, and Stephen Oh, MD, PhD, discuss polycythemia vera (PV) and the possible therapies that can be used to treat patients.

Understanding Essential Thrombocythemia And Treatment Options

January 24th 2022

Stephen Oh, MD, PhD, and Ruben Mesa, MD, explain the fundamentals of essential thrombocythemia (ET) and its treatment options.

Dr. Mesa on Future Research Efforts With JAK Inhibitors in Myelofibrosis

January 21st 2022

Ruben A. Mesa, MD, director of the Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center, discusses future research efforts with JAK inhibitors in myelofibrosis.

Dr. Harrison on Unmet Needs in Myelofibrosis

January 19th 2022

Claire Harrison, MD, FRCP, FRCPath, discusses current unmet needs in myelofibrosis.

Dr. Gerds on the Rationale for the Real-World REVEAL Study in Polycythemia Vera

January 17th 2022

Aaron T. Gerds, MD, MS, discusses the rationale for the real-world REVEAL study in polycythemia vera.

x